Table 1.
Baseline characteristics of the study population.
| Characteristic | Patients (n = 143) |
|---|---|
| Age, years: mean ± SD | 64 ± 10 |
| Gender: n (%) | |
| Men | 76 (52.8) |
| Women | 67 (46.9) |
| Comorbidities/past medical history: n (%) | |
| Coronary artery disease | 56 (39.2) |
| Diabetes mellitus | 56 (39.2) |
| Peripheral artery disease | 17 (11.9) |
| History of myocardial infarction | 16 (11.2) |
| History of myalgias | 10 (7.0) |
| Chronic liver disease | 2 (1.4) |
| History of rhabdomyolysis | 0 (0) |
| Statin: n (%) | |
| Simvastatin | 85 (59.4) |
| Atorvastatin | 45 (31.5) |
| Lovastatin | 6 (4.2) |
| Rosuvastatin | 4 (2.8) |
| Pravastatin | 2 (1.4) |
| Fluvastatin | 1 (0.7) |
| Additional lipid-lowering medication: n (%) | |
| Ezetimibe | 15 (10.5) |
| Gemfibrozil | 6 (4.2) |
| Fenofibrate | 5 (3.5) |
| Niacin | 3 (2.1) |
| Bile acid sequestrant | 2 (1.4) |
| Total number of medications a: mean ± SD | 7.9 ± 3.6 |
a
Total medications: determined at the last visit in the inclusion period. Oral and injectable chronic medications were included based on the patients’ medication list at that visit.
n, population size; SD, standard deviation.